Compare iShares MSCI South Korea ETF (EWY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Repligen Corporation Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $150.94 (market cap $22.66B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: iShares MSCI South Korea ETF is far larger — about 2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Repligen Corporation Common Stock for 0 Days on average.
| EWY | RGEN | |
|---|---|---|
Market Cap | $22.66B | $11.31B |
Volume | 17,900,400 | 1,216,919 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $194.57 |
52-Week Low | $85.17 | $102.87 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.56, down 2.16% amid bearish technical signals. The ETF faces pressure from rising US yields and oil prices impacting South Korean tech stocks, though corporate earnings remain resilient with strong AI memory demand driving performance. Technical indicators show oversold conditions with RSI at 21.77 suggesting potential bounce.
Outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to semiconductor cycle volatility. While AI infrastructure spending provides growth catalyst, macroeconomic headwinds and profit-taking near 7,000 KOSPI level present near-term risks for investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
